-
2
-
-
0028845212
-
Cytokine receptor signalling
-
Ihle JN. Cytokine receptor signalling. Nature 1995; 377:591-4.
-
(1995)
Nature
, vol.377
, pp. 591-594
-
-
Ihle, J.N.1
-
3
-
-
0034693871
-
Janus kinases: Components of multiple signaling pathways
-
Rane SG, Reddy EP. Janus kinases: components of multiple signaling pathways. Oncogene 2000; 19:5662-79.
-
(2000)
Oncogene
, vol.19
, pp. 5662-5679
-
-
Rane, S.G.1
Reddy, E.P.2
-
4
-
-
19944427133
-
The Janus kinases (Jaks)
-
Yamaoka K, Saharinen P, Pesu M, Holt VE, 3rd, Silvennoinen O, O'Shea JJ. The Janus kinases (Jaks). Genome Biol 2004; 5:253.
-
(2004)
Genome Biol
, vol.5
, pp. 253
-
-
Yamaoka, K.1
Saharinen, P.2
Pesu, M.3
Holt 3rd, V.E.4
Silvennoinen, O.5
O'Shea, J.J.6
-
5
-
-
35348850734
-
Hematopoietic cytokine receptor signaling
-
Baker SJ, Rane SG, Reddy EP. Hematopoietic cytokine receptor signaling. Oncogene 2007; 26:6724-37.
-
(2007)
Oncogene
, vol.26
, pp. 6724-6737
-
-
Baker, S.J.1
Rane, S.G.2
Reddy, E.P.3
-
6
-
-
33847393317
-
Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia
-
Malinge S, Ben Abdelali R, Settegrana C, Radford Weiss I, Debre M, Beldjord K, Macintyre EA, Villeval JL, Vainchenker W, Berger R, Bernard OA, Delabesse E, Penard Lacronique V. Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia. Blood 2007; 109:2202-4.
-
(2007)
Blood
, vol.109
, pp. 2202-2204
-
-
Malinge, S.1
Ben Abdelali, R.2
Settegrana, C.3
Radford Weiss, I.4
Debre, M.5
Beldjord, K.6
Macintyre, E.A.7
Villeval, J.L.8
Vainchenker, W.9
Berger, R.10
Bernard, O.A.11
Delabesse, E.12
Penard Lacronique, V.13
-
7
-
-
0037033012
-
The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction
-
Saharinen P, Silvennoinen O. The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. J Biol Chem 2002; 277:47954-63.
-
(2002)
J Biol Chem
, vol.277
, pp. 47954-47963
-
-
Saharinen, P.1
Silvennoinen, O.2
-
8
-
-
0034012330
-
Regulation of the Jak2 tyrosine kinase by its pseudokinase domain
-
Saharinen P, Takaluoma K, Silvennoinen O. Regulation of the Jak2 tyrosine kinase by its pseudokinase domain. Mol Cell Biol 2000; 20:3387-95.
-
(2000)
Mol Cell Biol
, vol.20
, pp. 3387-3395
-
-
Saharinen, P.1
Takaluoma, K.2
Silvennoinen, O.3
-
9
-
-
29644439240
-
JAK1 and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation: Cross-talk with IGF1 receptor
-
Staerk J, Kallin A, Demoulin JB, Vainchenker W, Constantinescu SN. JAK1 and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation: cross-talk with IGF1 receptor. J Biol Chem 2005; 280:41893-9.
-
(2005)
J Biol Chem
, vol.280
, pp. 41893-41899
-
-
Staerk, J.1
Kallin, A.2
Demoulin, J.B.3
Vainchenker, W.4
Constantinescu, S.N.5
-
10
-
-
0036731485
-
Stats: Transcriptional control and biological impact
-
Levy DE, Darnell JE, Jr. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 2002; 3:651-62.
-
(2002)
Nat Rev Mol Cell Biol
, vol.3
, pp. 651-662
-
-
Levy, D.E.1
Darnell Jr, J.E.2
-
11
-
-
25844469587
-
-
Griesinger F, Hennig H, Hillmer F, Podleschny M, Steffens R, Pies A, Wormann B, Haase D, Bohlander SK. A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia. Genes Chromosomes Cancer 2005; 44:329-33. 12. Lacronique V, Boureux A, Monni R, Dumon S, Mauchauffe M, Mayeux P, Gouilleux F, Berger R, Gisselbrecht S, Ghysdael J, Bernard OA. Transforming properties of chimeric TEL-JAK proteins in Ba/F3 cells. Blood 2000; 95:2076-83.
-
Griesinger F, Hennig H, Hillmer F, Podleschny M, Steffens R, Pies A, Wormann B, Haase D, Bohlander SK. A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia. Genes Chromosomes Cancer 2005; 44:329-33. 12. Lacronique V, Boureux A, Monni R, Dumon S, Mauchauffe M, Mayeux P, Gouilleux F, Berger R, Gisselbrecht S, Ghysdael J, Bernard OA. Transforming properties of chimeric TEL-JAK proteins in Ba/F3 cells. Blood 2000; 95:2076-83.
-
-
-
-
12
-
-
0030852328
-
-
Peeters P, Raynaud SD, Cools J, Wlodarska I, Grosgeorge J, Philip P, Monpoux F, Van Rompaey L, Baens M, Van den Berghe H, Marynen P. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood 1997; 90:2535-40.
-
Peeters P, Raynaud SD, Cools J, Wlodarska I, Grosgeorge J, Philip P, Monpoux F, Van Rompaey L, Baens M, Van den Berghe H, Marynen P. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood 1997; 90:2535-40.
-
-
-
-
13
-
-
20144389913
-
The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2
-
Reiter A, Walz C, Watmore A, Schoch C, Blau I, Schlegelberger B, Berger U, Telford N, Aruliah S, Yin JA, Vanstraelen D, Barker HF, Taylor PC, O'Driscoll A, Benedetti F, Rudolph C, Kolb HJ, Hochhaus A, Hehlmann R, Chase A, Cross NC. The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Res 2005; 65:2662-7.
-
(2005)
Cancer Res
, vol.65
, pp. 2662-2667
-
-
Reiter, A.1
Walz, C.2
Watmore, A.3
Schoch, C.4
Blau, I.5
Schlegelberger, B.6
Berger, U.7
Telford, N.8
Aruliah, S.9
Yin, J.A.10
Vanstraelen, D.11
Barker, H.F.12
Taylor, P.C.13
O'Driscoll, A.14
Benedetti, F.15
Rudolph, C.16
Kolb, H.J.17
Hochhaus, A.18
Hehlmann, R.19
Chase, A.20
Cross, N.C.21
more..
-
14
-
-
33947328520
-
Oncogenes in myeloproliferative disorders
-
Tefferi A, Gilliland DG. Oncogenes in myeloproliferative disorders. Cell Cycle 2007; 6:550-66.
-
(2007)
Cell Cycle
, vol.6
, pp. 550-566
-
-
Tefferi, A.1
Gilliland, D.G.2
-
15
-
-
27944481825
-
The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene
-
Bousquet M, Quelen C, De Mas V, Duchayne E, Roquefeuil B, Delsol G, Laurent G, Dastugue N, Brousset P. The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene. Oncogene 2005; 24:7248-52.
-
(2005)
Oncogene
, vol.24
, pp. 7248-7252
-
-
Bousquet, M.1
Quelen, C.2
De Mas, V.3
Duchayne, E.4
Roquefeuil, B.5
Delsol, G.6
Laurent, G.7
Dastugue, N.8
Brousset, P.9
-
16
-
-
26944481210
-
PCM1-JAK2 fusion in myeloproliferative disorders and acute erythroid leukemia with t(8;9) translocation
-
Murati A, Gelsi Boyer V, Adelaide J, Perot C, Talmant P, Giraudier S, Lode L, Letessier A, Delaval B, Brunel V, Imbert M, Garand R, Xerri L, Birnbaum D, Mozziconacci MJ, Chaffanet M. PCM1-JAK2 fusion in myeloproliferative disorders and acute erythroid leukemia with t(8;9) translocation. Leukemia 2005; 19:1692-6.
-
(2005)
Leukemia
, vol.19
, pp. 1692-1696
-
-
Murati, A.1
Gelsi Boyer, V.2
Adelaide, J.3
Perot, C.4
Talmant, P.5
Giraudier, S.6
Lode, L.7
Letessier, A.8
Delaval, B.9
Brunel, V.10
Imbert, M.11
Garand, R.12
Xerri, L.13
Birnbaum, D.14
Mozziconacci, M.J.15
Chaffanet, M.16
-
17
-
-
33846216449
-
Jak2: Normal function and role in hematopoietic disorders
-
Ihle JN, Gilliland DG. Jak2: normal function and role in hematopoietic disorders. Curr Opin Genet Dev 2007; 17:8-14.
-
(2007)
Curr Opin Genet Dev
, vol.17
, pp. 8-14
-
-
Ihle, J.N.1
Gilliland, D.G.2
-
18
-
-
0029031668
-
Activation of a Drosophila Janus kinase (JAK) causes hematopoietic neoplasia and developmental defects
-
Harrison DA, Binari R, Nahreini TS, Gilman M, Perrimon N. Activation of a Drosophila Janus kinase (JAK) causes hematopoietic neoplasia and developmental defects. Embo J 1995; 14:2857-65.
-
(1995)
Embo J
, vol.14
, pp. 2857-2865
-
-
Harrison, D.A.1
Binari, R.2
Nahreini, T.S.3
Gilman, M.4
Perrimon, N.5
-
19
-
-
0028938172
-
An amino acid substitution in the Drosophila hopTum-l Jak kinase causes leukemia-like hematopoietic defects
-
Luo H, Hanratty WP, Dearolf CR. An amino acid substitution in the Drosophila hopTum-l Jak kinase causes leukemia-like hematopoietic defects. Embo J 1995; 14:1412-20.
-
(1995)
Embo J
, vol.14
, pp. 1412-1420
-
-
Luo, H.1
Hanratty, W.P.2
Dearolf, C.R.3
-
20
-
-
0031017533
-
Mutation in the Jak kinase JH2 domain hyperactivates Drosophila and mammalian Jak-Stat pathways
-
Luo H, Rose P, Barber D, Hanratty WP, Lee S, Roberts TM, D'Andrea AD, Dearolf CR. Mutation in the Jak kinase JH2 domain hyperactivates Drosophila and mammalian Jak-Stat pathways. Mol Cell Biol 1997; 17:1562-71.
-
(1997)
Mol Cell Biol
, vol.17
, pp. 1562-1571
-
-
Luo, H.1
Rose, P.2
Barber, D.3
Hanratty, W.P.4
Lee, S.5
Roberts, T.M.6
D'Andrea, A.D.7
Dearolf, C.R.8
-
21
-
-
33845436745
-
The myeloproliferative disorders
-
Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med 2006; 355:2452-66.
-
(2006)
N Engl J Med
, vol.355
, pp. 2452-2466
-
-
Campbell, P.J.1
Green, A.R.2
-
22
-
-
0001639195
-
Some speculations on the myeloproliferative syndromes
-
Dameshek W. Some speculations on the myeloproliferative syndromes. Blood 1951; 6:372-5.
-
(1951)
Blood
, vol.6
, pp. 372-375
-
-
Dameshek, W.1
-
23
-
-
34548240698
-
Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders
-
Levine RL, Pardanani A, Tefferi A, Gilliland DG. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 2007; 7:673-83.
-
(2007)
Nat Rev Cancer
, vol.7
, pp. 673-683
-
-
Levine, R.L.1
Pardanani, A.2
Tefferi, A.3
Gilliland, D.G.4
-
24
-
-
20144363192
-
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
-
Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, Green AR. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365:1054-61.
-
(2005)
Lancet
, vol.365
, pp. 1054-1061
-
-
Baxter, E.J.1
Scott, L.M.2
Campbell, P.J.3
East, C.4
Fourouclas, N.5
Swanton, S.6
Vassiliou, G.S.7
Bench, A.J.8
Boyd, E.M.9
Curtin, N.10
Scott, M.A.11
Erber, W.N.12
Green, A.R.13
-
25
-
-
17844383458
-
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
-
James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, Garcon L, Raslova H, Berger R, Bennaceur Griscelli A, Villeval JL, Constantinescu SN, Casadevall N, Vainchenker W. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434:1144-8.
-
(2005)
Nature
, vol.434
, pp. 1144-1148
-
-
James, C.1
Ugo, V.2
Le Couedic, J.P.3
Staerk, J.4
Delhommeau, F.5
Lacout, C.6
Garcon, L.7
Raslova, H.8
Berger, R.9
Bennaceur Griscelli, A.10
Villeval, J.L.11
Constantinescu, S.N.12
Casadevall, N.13
Vainchenker, W.14
-
26
-
-
17644424955
-
A gain-of-function mutation of JAK2 in myeloproliferative disorders
-
Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352:1779-90.
-
(2005)
N Engl J Med
, vol.352
, pp. 1779-1790
-
-
Kralovics, R.1
Passamonti, F.2
Buser, A.S.3
Teo, S.S.4
Tiedt, R.5
Passweg, J.R.6
Tichelli, A.7
Cazzola, M.8
Skoda, R.C.9
-
27
-
-
20244369569
-
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
-
Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, Adelsperger J, Koo S, Lee JC, Gabriel S, Mercher T, D'Andrea A, Frohling S, Dohner K, Marynen P, Vandenberghe P, Mesa RA, Tefferi A, Griffin JD, Eck MJ, Sellers WR, Meyerson M, Golub TR, Lee SJ, Gilliland DG. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7:387-97.
-
(2005)
Cancer Cell
, vol.7
, pp. 387-397
-
-
Levine, R.L.1
Wadleigh, M.2
Cools, J.3
Ebert, B.L.4
Wernig, G.5
Huntly, B.J.6
Boggon, T.J.7
Wlodarska, I.8
Clark, J.J.9
Moore, S.10
Adelsperger, J.11
Koo, S.12
Lee, J.C.13
Gabriel, S.14
Mercher, T.15
D'Andrea, A.16
Frohling, S.17
Dohner, K.18
Marynen, P.19
Vandenberghe, P.20
Mesa, R.A.21
Tefferi, A.22
Griffin, J.D.23
Eck, M.J.24
Sellers, W.R.25
Meyerson, M.26
Golub, T.R.27
Lee, S.J.28
Gilliland, D.G.29
more..
-
28
-
-
20744460045
-
Identification of an acquired JAK2 mutation in polycythemia vera
-
Zhao R, Xing S, Li Z, Fu X, Li Q, Krantz SB, Zhao ZJ. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 2005; 280:22788-92.
-
(2005)
J Biol Chem
, vol.280
, pp. 22788-22792
-
-
Zhao, R.1
Xing, S.2
Li, Z.3
Fu, X.4
Li, Q.5
Krantz, S.B.6
Zhao, Z.J.7
-
29
-
-
21344467318
-
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders
-
Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L, Score J, Seear R, Chase AJ, Grand FH, White H, Zoi C, Loukopoulos D, Terpos E, Vervessou EC, Schultheis B, Emig M, Ernst T, Lengfelder E, Hehlmann R, Hochhaus A, Oscier D, Silver RT, Reiter A, Cross NC. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005; 106:2162-8.
-
(2005)
Blood
, vol.106
, pp. 2162-2168
-
-
Jones, A.V.1
Kreil, S.2
Zoi, K.3
Waghorn, K.4
Curtis, C.5
Zhang, L.6
Score, J.7
Seear, R.8
Chase, A.J.9
Grand, F.H.10
White, H.11
Zoi, C.12
Loukopoulos, D.13
Terpos, E.14
Vervessou, E.C.15
Schultheis, B.16
Emig, M.17
Ernst, T.18
Lengfelder, E.19
Hehlmann, R.20
Hochhaus, A.21
Oscier, D.22
Silver, R.T.23
Reiter, A.24
Cross, N.C.25
more..
-
30
-
-
33845355846
-
JAK-2 mutations and their relevance to myeloproliferative disease
-
Levine RL, Gilliland DG. JAK-2 mutations and their relevance to myeloproliferative disease. Curr Opin Hematol 2007; 14:43-7.
-
(2007)
Curr Opin Hematol
, vol.14
, pp. 43-47
-
-
Levine, R.L.1
Gilliland, D.G.2
-
31
-
-
42049086740
-
A Role for JAK2 Mutations in Myeloproliferative Diseases
-
Morgan KJ, Gilliland DG. A Role for JAK2 Mutations in Myeloproliferative Diseases. Annu Rev Med 2007.
-
(2007)
Annu Rev Med
-
-
Morgan, K.J.1
Gilliland, D.G.2
-
32
-
-
34848840612
-
Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders
-
Pikman Y, Levine RL. Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders. Curr Opin Oncol 2007; 19:628-34.
-
(2007)
Curr Opin Oncol
, vol.19
, pp. 628-634
-
-
Pikman, Y.1
Levine, R.L.2
-
33
-
-
33947128676
-
JAK2, the JAK2 V617F mutant and cytokine receptors
-
Staerk J, Kallin A, Royer Y, Diaconu CC, Dusa A, Demoulin JB, Vainchenker W, Constantinescu SN. JAK2, the JAK2 V617F mutant and cytokine receptors. Pathol Biol (Paris) 2007; 55:88-91.
-
(2007)
Pathol Biol (Paris)
, vol.55
, pp. 88-91
-
-
Staerk, J.1
Kallin, A.2
Royer, Y.3
Diaconu, C.C.4
Dusa, A.5
Demoulin, J.B.6
Vainchenker, W.7
Constantinescu, S.N.8
-
34
-
-
25444513652
-
JAK2 in myeloproliferative disorders is not just another kinase
-
Tefferi A, Gilliland DG. JAK2 in myeloproliferative disorders is not just another kinase. Cell Cycle 2005; 4:1053-6.
-
(2005)
Cell Cycle
, vol.4
, pp. 1053-1056
-
-
Tefferi, A.1
Gilliland, D.G.2
-
35
-
-
33846037739
-
Oncogenic mechanisms in myeloproliferative disorders
-
Delhommeau F, Pisani DF, James C, Casadevall N, Constantinescu S, Vainchenker W. Oncogenic mechanisms in myeloproliferative disorders. Cell Mol Life Sci 2006; 63:2939-53.
-
(2006)
Cell Mol Life Sci
, vol.63
, pp. 2939-2953
-
-
Delhommeau, F.1
Pisani, D.F.2
James, C.3
Casadevall, N.4
Constantinescu, S.5
Vainchenker, W.6
-
36
-
-
39749130423
-
JAK2 mutations and clinical practice in myeloproliferative neoplasms
-
Tefferi A. JAK2 mutations and clinical practice in myeloproliferative neoplasms. Cancer J 2007; 13:366-71.
-
(2007)
Cancer J
, vol.13
, pp. 366-371
-
-
Tefferi, A.1
-
37
-
-
38549152801
-
Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms
-
Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2007.
-
(2007)
Leukemia
-
-
Tefferi, A.1
Vardiman, J.W.2
-
38
-
-
33845798378
-
Characterization of murine JAK2V617F-positive myeloproliferative disease
-
Bumm TG, Elsea C, Corbin AS, Loriaux M, Sherbenou D, Wood L, Deininger J, Silver RT, Druker BJ, Deininger MW. Characterization of murine JAK2V617F-positive myeloproliferative disease. Cancer Res 2006; 66:11156-65.
-
(2006)
Cancer Res
, vol.66
, pp. 11156-11165
-
-
Bumm, T.G.1
Elsea, C.2
Corbin, A.S.3
Loriaux, M.4
Sherbenou, D.5
Wood, L.6
Deininger, J.7
Silver, R.T.8
Druker, B.J.9
Deininger, M.W.10
-
39
-
-
33745721197
-
JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis
-
Lacout C, Pisani DF, Tulliez M, Gachelin FM, Vainchenker W, Villeval JL. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 2006; 108:1652-60.
-
(2006)
Blood
, vol.108
, pp. 1652-1660
-
-
Lacout, C.1
Pisani, D.F.2
Tulliez, M.3
Gachelin, F.M.4
Vainchenker, W.5
Villeval, J.L.6
-
40
-
-
33744490974
-
Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model
-
Wernig G, Mercher T, Okabe R, Levine RL, Lee BH, Gilliland DG. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 2006; 107:4274-81.
-
(2006)
Blood
, vol.107
, pp. 4274-4281
-
-
Wernig, G.1
Mercher, T.2
Okabe, R.3
Levine, R.L.4
Lee, B.H.5
Gilliland, D.G.6
-
41
-
-
34447642422
-
Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F
-
Zaleskas VM, Krause DS, Lazarides K, Patel N, Hu Y, Li S, Van Etten RA. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. PLoS ONE 2006; 1:18.
-
(2006)
PLoS ONE
, vol.1
, pp. 18
-
-
Zaleskas, V.M.1
Krause, D.S.2
Lazarides, K.3
Patel, N.4
Hu, Y.5
Li, S.6
Van Etten, R.A.7
-
42
-
-
85011937299
-
-
Tiedt R, Hao Shen H, Sobas MA, Looser R, Dirnhofer S, Schwaller J, Skoda RC. Ratio of mutant JAK2-V617F to wild type JAK2 determines the MPD phenotypes in transgenic mice. Blood 2007.
-
Tiedt R, Hao Shen H, Sobas MA, Looser R, Dirnhofer S, Schwaller J, Skoda RC. Ratio of mutant JAK2-V617F to wild type JAK2 determines the MPD phenotypes in transgenic mice. Blood 2007.
-
-
-
-
43
-
-
42049102005
-
The JAK2(V617F) mutation may be present several years before the occurrence of overt myeloproliferative disorders
-
Bellanne Chantelot C, Jego P, Lionne Huyghe P, Tulliez M, Najman A. The JAK2(V617F) mutation may be present several years before the occurrence of overt myeloproliferative disorders. Leukemia 2007.
-
(2007)
Leukemia
-
-
Bellanne Chantelot, C.1
Jego, P.2
Lionne Huyghe, P.3
Tulliez, M.4
Najman, A.5
-
44
-
-
33750611344
-
Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera
-
Ishii T, Bruno E, Hoffman R, Xu M. Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera. Blood 2006; 108:3128-34.
-
(2006)
Blood
, vol.108
, pp. 3128-3134
-
-
Ishii, T.1
Bruno, E.2
Hoffman, R.3
Xu, M.4
-
45
-
-
33747199312
-
Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders
-
Kralovics R, Teo SS, Li S, Theocharides A, Buser AS, Tichelli A, Skoda RC. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood 2006; 108:1377-80.
-
(2006)
Blood
, vol.108
, pp. 1377-1380
-
-
Kralovics, R.1
Teo, S.S.2
Li, S.3
Theocharides, A.4
Buser, A.S.5
Tichelli, A.6
Skoda, R.C.7
-
46
-
-
33750515447
-
JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders
-
Rumi E, Passamonti F, Pietra D, Della Porta MG, Arcaini L, Boggi S, Elena C, Boveri E, Pascutto C, Lazzarino M, Cazzola M. JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders. Cancer 2006; 107:2206-11.
-
(2006)
Cancer
, vol.107
, pp. 2206-2211
-
-
Rumi, E.1
Passamonti, F.2
Pietra, D.3
Della Porta, M.G.4
Arcaini, L.5
Boggi, S.6
Elena, C.7
Boveri, E.8
Pascutto, C.9
Lazzarino, M.10
Cazzola, M.11
-
47
-
-
33846660947
-
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis
-
Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR, Futreal PA, Erber WN, McMullin MF, Harrison CN, Warren AJ, Gilliland DG, Lodish HF, Green AR. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007; 356:459-68.
-
(2007)
N Engl J Med
, vol.356
, pp. 459-468
-
-
Scott, L.M.1
Tong, W.2
Levine, R.L.3
Scott, M.A.4
Beer, P.A.5
Stratton, M.R.6
Futreal, P.A.7
Erber, W.N.8
McMullin, M.F.9
Harrison, C.N.10
Warren, A.J.11
Gilliland, D.G.12
Lodish, H.F.13
Green, A.R.14
-
48
-
-
39749128600
-
Two novel JAK2 exon 12 mutations in JAK2V617F-negative polycythaemia vera patients
-
Butcher CM, Hahn U, To LB, Gecz J, Wilkins EJ, Scott HS, Bardy PG, D'Andrea RJ. Two novel JAK2 exon 12 mutations in JAK2V617F-negative polycythaemia vera patients. Leukemia 2007.
-
(2007)
Leukemia
-
-
Butcher, C.M.1
Hahn, U.2
To, L.B.3
Gecz, J.4
Wilkins, E.J.5
Scott, H.S.6
Bardy, P.G.7
D'Andrea, R.J.8
-
49
-
-
34848910714
-
Prevalance of JAK2 V617F and exon 12 mutations in polycythaemia vera
-
Scott LM, Beer PA, Bench AJ, Erber WN, Green AR. Prevalance of JAK2 V617F and exon 12 mutations in polycythaemia vera. Br J Haematol 2007; 139:511-2.
-
(2007)
Br J Haematol
, vol.139
, pp. 511-512
-
-
Scott, L.M.1
Beer, P.A.2
Bench, A.J.3
Erber, W.N.4
Green, A.R.5
-
50
-
-
33748206336
-
L overexpression can induce endogenous erythroid colony formation in human primary cells
-
L overexpression can induce endogenous erythroid colony formation in human primary cells. Blood 2006; 108:1551-4.
-
(2006)
Blood
, vol.108
, pp. 1551-1554
-
-
Garcon, L.1
Rivat, C.2
James, C.3
Lacout, C.4
Camara Clayette, V.5
Ugo, V.6
Lecluse, Y.7
Bennaceur Griscelli, A.8
Vainchenker, W.9
-
51
-
-
34547673400
-
Applying the discovery of the Philadelphia chromosome
-
Sherbenou DW, Druker BJ. Applying the discovery of the Philadelphia chromosome. J Clin Invest 2007; 117:2067-74.
-
(2007)
J Clin Invest
, vol.117
, pp. 2067-2074
-
-
Sherbenou, D.W.1
Druker, B.J.2
-
52
-
-
38149123436
-
JAK2 inhibitor therapy in myeloproliferative disorders: Rationale, preclinical studies and ongoing clinical trials
-
Pardanani A. JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials. Leukemia 2007.
-
(2007)
Leukemia
-
-
Pardanani, A.1
-
53
-
-
34447627350
-
TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations
-
Pardanani A, Hood J, Lasho T, Levine RL, Martin MB, Noronha G, Finke C, Mak CC, Mesa R, Zhu H, Soll R, Gilliland DG, Tefferi A. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia 2007; 21:1658-68.
-
(2007)
Leukemia
, vol.21
, pp. 1658-1668
-
-
Pardanani, A.1
Hood, J.2
Lasho, T.3
Levine, R.L.4
Martin, M.B.5
Noronha, G.6
Finke, C.7
Mak, C.C.8
Mesa, R.9
Zhu, H.10
Soll, R.11
Gilliland, D.G.12
Tefferi, A.13
-
54
-
-
33749434271
-
Mutation of JAK2 in the myeloproliferative disorders: Timing, clonality studies, cytogenetic associations and role in leukemic transformation
-
Campbell PJ, Baxter EJ, Beer PA, Scott LM, Bench AJ, Huntly BJ, Erber WN, Kusec R, Larsen TS, Giraudier S, Le Bousse Kerdiles MC, Griesshammer M, Reilly JT, Cheung BY, Harrison CN, Green AR. Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations and role in leukemic transformation. Blood 2006; 108:3548-55.
-
(2006)
Blood
, vol.108
, pp. 3548-3555
-
-
Campbell, P.J.1
Baxter, E.J.2
Beer, P.A.3
Scott, L.M.4
Bench, A.J.5
Huntly, B.J.6
Erber, W.N.7
Kusec, R.8
Larsen, T.S.9
Giraudier, S.10
Le Bousse Kerdiles, M.C.11
Griesshammer, M.12
Reilly, J.T.13
Cheung, B.Y.14
Harrison, C.N.15
Green, A.R.16
-
55
-
-
34347394712
-
Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation
-
Theocharides A, Boissinot M, Girodon F, Garand R, Teo SS, Lippert E, Talmant P, Tichelli A, Hermouet S, Skoda RC. Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood 2007; 110:375-9.
-
(2007)
Blood
, vol.110
, pp. 375-379
-
-
Theocharides, A.1
Boissinot, M.2
Girodon, F.3
Garand, R.4
Teo, S.S.5
Lippert, E.6
Talmant, P.7
Tichelli, A.8
Hermouet, S.9
Skoda, R.C.10
-
56
-
-
30044437118
-
Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation
-
Lu X, Levine R, Tong W, Wernig G, Pikman Y, Zarnegar S, Gilliland DG, Lodish H. Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proc Natl Acad Sci USA 2005; 102:18962-7.
-
(2005)
Proc Natl Acad Sci USA
, vol.102
, pp. 18962-18967
-
-
Lu, X.1
Levine, R.2
Tong, W.3
Wernig, G.4
Pikman, Y.5
Zarnegar, S.6
Gilliland, D.G.7
Lodish, H.8
-
57
-
-
42049115866
-
Dimerization by a cytokine receptor is necessary for constitutive activation of JAK2V617F
-
Lu X, Huang LJ, Lodish HF. Dimerization by a cytokine receptor is necessary for constitutive activation of JAK2V617F. J Biol Chem 2007.
-
(2007)
J Biol Chem
-
-
Lu, X.1
Huang, L.J.2
Lodish, H.F.3
-
58
-
-
33746437130
-
MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia
-
Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, Cuker A, Wernig G, Moore S, Galinsky I, DeAngelo DJ, Clark JJ, Lee SJ, Golub TR, Wadleigh M, Gilliland DG, Levine RL. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006; 3:270.
-
(2006)
PLoS Med
, vol.3
, pp. 270
-
-
Pikman, Y.1
Lee, B.H.2
Mercher, T.3
McDowell, E.4
Ebert, B.L.5
Gozo, M.6
Cuker, A.7
Wernig, G.8
Moore, S.9
Galinsky, I.10
DeAngelo, D.J.11
Clark, J.J.12
Lee, S.J.13
Golub, T.R.14
Wadleigh, M.15
Gilliland, D.G.16
Levine, R.L.17
-
59
-
-
33750534561
-
MPL515 mutations in myeloproliferative and other myeloid disorders: A study of 1182 patients
-
Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M, Steensma DP, Elliott MA, Wolanskyj AP, Hogan WJ, McClure RF, Litzow MR, Gilliland DG, Tefferi A. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006; 108:3472-6.
-
(2006)
Blood
, vol.108
, pp. 3472-3476
-
-
Pardanani, A.D.1
Levine, R.L.2
Lasho, T.3
Pikman, Y.4
Mesa, R.A.5
Wadleigh, M.6
Steensma, D.P.7
Elliott, M.A.8
Wolanskyj, A.P.9
Hogan, W.J.10
McClure, R.F.11
Litzow, M.R.12
Gilliland, D.G.13
Tefferi, A.14
-
60
-
-
2542502506
-
Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin
-
Ding J, Komatsu H, Wakita A, Kato Uranishi M, Ito M, Satoh A, Tsuboi K, Nitta M, Miyazaki H, Iida S, Ueda R. Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood 2004; 103:4198-200.
-
(2004)
Blood
, vol.103
, pp. 4198-4200
-
-
Ding, J.1
Komatsu, H.2
Wakita, A.3
Kato Uranishi, M.4
Ito, M.5
Satoh, A.6
Tsuboi, K.7
Nitta, M.8
Miyazaki, H.9
Iida, S.10
Ueda, R.11
-
61
-
-
36749024030
-
Transformation of hematopoietic cells and activation of JAK2-V617F by IL-27R, a component of a heterodimeric type I cytokine receptor
-
Pradhan A, Lambert QT, Reuther GW. Transformation of hematopoietic cells and activation of JAK2-V617F by IL-27R, a component of a heterodimeric type I cytokine receptor. Proc Natl Acad Sci USA 2007; 104:18502-7.
-
(2007)
Proc Natl Acad Sci USA
, vol.104
, pp. 18502-18507
-
-
Pradhan, A.1
Lambert, Q.T.2
Reuther, G.W.3
-
62
-
-
0032495990
-
Cloning and characterization of a novel class I cytokine receptor
-
Sprecher CA, Grant FJ, Baumgartner JW, Presnell SR, Schrader SK, Yamagiwa T, Whitmore TE, O'Hara PJ, Foster DF. Cloning and characterization of a novel class I cytokine receptor. Biochem Biophys Res Commun 1998; 246:82-90.
-
(1998)
Biochem Biophys Res Commun
, vol.246
, pp. 82-90
-
-
Sprecher, C.A.1
Grant, F.J.2
Baumgartner, J.W.3
Presnell, S.R.4
Schrader, S.K.5
Yamagiwa, T.6
Whitmore, T.E.7
O'Hara, P.J.8
Foster, D.F.9
-
63
-
-
3142709474
-
Understanding the pro- and anti-inflammatory properties of IL-27
-
Villarino AV, Huang E, Hunter CA. Understanding the pro- and anti-inflammatory properties of IL-27. J Immunol 2004; 173:715-20.
-
(2004)
J Immunol
, vol.173
, pp. 715-720
-
-
Villarino, A.V.1
Huang, E.2
Hunter, C.A.3
-
64
-
-
10744222574
-
WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27
-
Pflanz S, Hibbert L, Mattson J, Rosales R, Vaisberg E, Bazan JF, Phillips JH, McClanahan TK, de Waal Malefyt R, Kastelein RA. WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. J Immunol 2004; 172:2225-31.
-
(2004)
J Immunol
, vol.172
, pp. 2225-2231
-
-
Pflanz, S.1
Hibbert, L.2
Mattson, J.3
Rosales, R.4
Vaisberg, E.5
Bazan, J.F.6
Phillips, J.H.7
McClanahan, T.K.8
de Waal Malefyt, R.9
Kastelein, R.A.10
-
65
-
-
18444385868
-
IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4(+) T cells
-
Pflanz S, Timans JC, Cheung J, Rosales R, Kanzler H, Gilbert J, Hibbert L, Churakova T, Travis M, Vaisberg E, Blumenschein WM, Mattson JD, Wagner JL, To W, Zurawski S, McClanahan TK, Gorman DM, Bazan JF, de Waal Malefyt R, Rennick D, Kastelein RA. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4(+) T cells. Immunity 2002; 16:779-90.
-
(2002)
Immunity
, vol.16
, pp. 779-790
-
-
Pflanz, S.1
Timans, J.C.2
Cheung, J.3
Rosales, R.4
Kanzler, H.5
Gilbert, J.6
Hibbert, L.7
Churakova, T.8
Travis, M.9
Vaisberg, E.10
Blumenschein, W.M.11
Mattson, J.D.12
Wagner, J.L.13
To, W.14
Zurawski, S.15
McClanahan, T.K.16
Gorman, D.M.17
Bazan, J.F.18
de Waal Malefyt, R.19
Rennick, D.20
Kastelein, R.A.21
more..
-
66
-
-
85011940493
-
-
Seita J, Asakawa M, Ooehara J, Takayanagi SI, Morita Y, Watanabe N, Fujita K, Kudo M, Mizuguchi J, Ema H, Nakauchi H, Yoshimoto T. Interleukin-27 directly induces differentiation in hematopoietic stem cells. Blood 2007.
-
Seita J, Asakawa M, Ooehara J, Takayanagi SI, Morita Y, Watanabe N, Fujita K, Kudo M, Mizuguchi J, Ema H, Nakauchi H, Yoshimoto T. Interleukin-27 directly induces differentiation in hematopoietic stem cells. Blood 2007.
-
-
-
-
67
-
-
21844444831
-
-
Hunter CA. New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat Rev Immunol 2005; 5:521-31.
-
Hunter CA. New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat Rev Immunol 2005; 5:521-31.
-
-
-
-
68
-
-
26444605552
-
WSX-1 overexpression in CD4(+) T cells leads to hyperproliferation and cytokine hyperproduction in response to TCR stimulation
-
Takeda A, Hamano S, Shiraishi H, Yoshimura T, Ogata H, Ishii K, Ishibashi T, Yoshimura A, Yoshida H. WSX-1 overexpression in CD4(+) T cells leads to hyperproliferation and cytokine hyperproduction in response to TCR stimulation. Int Immunol 2005; 17:889-97.
-
(2005)
Int Immunol
, vol.17
, pp. 889-897
-
-
Takeda, A.1
Hamano, S.2
Shiraishi, H.3
Yoshimura, T.4
Ogata, H.5
Ishii, K.6
Ishibashi, T.7
Yoshimura, A.8
Yoshida, H.9
-
69
-
-
0346157324
-
Acquiring signalling specificity from the cytokine receptor gp130
-
Ernst M, Jenkins BJ. Acquiring signalling specificity from the cytokine receptor gp130. Trends Genet 2004; 20:23-32.
-
(2004)
Trends Genet
, vol.20
, pp. 23-32
-
-
Ernst, M.1
Jenkins, B.J.2
-
70
-
-
0026073694
-
Distribution and comparison of receptors for leukemia inhibitory factor on murine hemopoietic and hepatic cells
-
Hilton DJ, Nicola NA, Metcalf D. Distribution and comparison of receptors for leukemia inhibitory factor on murine hemopoietic and hepatic cells. J Cell Physiol 1991; 146:207-15.
-
(1991)
J Cell Physiol
, vol.146
, pp. 207-215
-
-
Hilton, D.J.1
Nicola, N.A.2
Metcalf, D.3
-
71
-
-
12644294970
-
Dual oncostatin M (OSM) receptors. Cloning and characterization of an alternative signaling subunit conferring OSM-specific receptor activation
-
Mosley B, De Imus C, Friend D, Boiani N, Thoma B, Park LS, Cosman D. Dual oncostatin M (OSM) receptors. Cloning and characterization of an alternative signaling subunit conferring OSM-specific receptor activation. J Biol Chem 1996; 271:32635-43.
-
(1996)
J Biol Chem
, vol.271
, pp. 32635-32643
-
-
Mosley, B.1
De Imus, C.2
Friend, D.3
Boiani, N.4
Thoma, B.5
Park, L.S.6
Cosman, D.7
-
72
-
-
0030890718
-
Gp130 and the interleukin-6 family of cytokines
-
Taga T, Kishimoto T. Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol 1997; 15:797-819.
-
(1997)
Annu Rev Immunol
, vol.15
, pp. 797-819
-
-
Taga, T.1
Kishimoto, T.2
-
73
-
-
0034007126
-
Structural and functional studies on the leukemia inhibitory factor receptor (LIF-R): Gene and soluble form of LIF-R, and cytoplasmic domain of LIF-R required for differentiation and growth arrest of myeloid leukemic cells
-
Tomida M. Structural and functional studies on the leukemia inhibitory factor receptor (LIF-R): gene and soluble form of LIF-R, and cytoplasmic domain of LIF-R required for differentiation and growth arrest of myeloid leukemic cells. Leuk Lymphoma 2000; 37:517-25.
-
(2000)
Leuk Lymphoma
, vol.37
, pp. 517-525
-
-
Tomida, M.1
-
74
-
-
33750221616
-
Receptor specific downregulation of cytokine signaling by autophosphorylation in the FERM domain of Jak2
-
Funakoshi Tago M, Pelletier S, Matsuda T, Parganas E, Ihle JN. Receptor specific downregulation of cytokine signaling by autophosphorylation in the FERM domain of Jak2. Embo J 2006; 25:4763-72.
-
(2006)
Embo J
, vol.25
, pp. 4763-4772
-
-
Funakoshi Tago, M.1
Pelletier, S.2
Matsuda, T.3
Parganas, E.4
Ihle, J.N.5
-
75
-
-
33646381647
-
Active conformation of the erythropoietin receptor: Random and cysteine-scanning mutagenesis of the extracellular juxtamembrane and transmembrane domains
-
Lu X, Gross AW, Lodish HF. Active conformation of the erythropoietin receptor: random and cysteine-scanning mutagenesis of the extracellular juxtamembrane and transmembrane domains. J Biol Chem 2006; 281:7002-11.
-
(2006)
J Biol Chem
, vol.281
, pp. 7002-7011
-
-
Lu, X.1
Gross, A.W.2
Lodish, H.F.3
-
76
-
-
0028332086
-
Activation and inhibition of erythropoietin receptor function: Role of receptor dimerization
-
Watowich SS, Hilton DJ, Lodish HF. Activation and inhibition of erythropoietin receptor function: role of receptor dimerization. Mol Cell Biol 1994; 14:3535-49.
-
(1994)
Mol Cell Biol
, vol.14
, pp. 3535-3549
-
-
Watowich, S.S.1
Hilton, D.J.2
Lodish, H.F.3
|